Jeremy A. Aiss
About Jeremy A. Aiss
Jeremy A. Aiss is the Global Immunology and Fibrosis Lead for Business Analytics at Bristol Myers Squibb, with a background in life sciences strategy, finance portfolio management, and business analytics.
Current Role at Bristol Myers Squibb
Jeremy A. Aiss currently holds the position of Global Immunology and Fibrosis Lead, Business Analytics - Enterprise Strategy & Forecasting at Bristol Myers Squibb. In this role, he leads a cross-functional team to develop strategic forecasts for immunology and fibrosis therapies. His responsibilities include formulating business strategies and providing analytical insights for enterprise-wide forecasting in Princeton, New Jersey, United States.
Former Positions at Pfizer
Jeremy A. Aiss previously worked at Pfizer in multiple roles. From 2017 to 2020, he served as Associate Director, US Business Analytics & Insights - Eliquis, where he played a key role in the business analytics and insights for the cardiovascular drug Eliquis. Before that, he was the Finance Portfolio Management Optimization Lead from 2019 to 2020, focusing on optimizing the financial portfolio of the company. Both positions were based in the Greater New York City Area.
Consulting Experience in Life Sciences Strategy
Jeremy A. Aiss has considerable experience in life sciences strategy consulting. He worked as a Consultant at IQVIA from 2016 to 2017, and as a Senior Consultant at Navigant from 2014 to 2016. In these roles, he specialized in consulting for the life sciences industry, providing strategic advice and insights to clients in the Greater New York City Area.
Finance and Equity Research Background
From 2013 to 2014, Jeremy held the position of Equity Research Graduate Associate at Brean Capital, LLC. His focus at the firm was on medical technology and devices. His responsibilities included conducting detailed equity research and providing insights that supported investment decisions.
Educational Background
Jeremy A. Aiss has a diverse educational background that supports his professional expertise. He earned a BS from Fordham University, followed by an MS from New York Medical College. He also achieved an MBA from the Fordham Gabelli School of Business and a certificate from The Wharton School, equipping him with comprehensive knowledge and skills in business and life sciences.